Cognitive Remediation Therapy for improving cognitive and emotional skills in schizophrenia
Official title: A Randomized Controlled EEG-GSR Study on the Effects of Cognitive Remediation Therapy on Neurophysiological and Emotional Regulation Markers in Schizophrenia
Run by Beykoz University · NCT06936397 · Data updated 2026-11-12
This study tests if Cognitive Remediation Therapy can help people with schizophrenia improve their thinking and emotional skills over 12 weeks.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Beykoz University Academic / other |
| Locations | 1 site (Istanbul) |
| Status | Recruiting |
| Started | March 15, 2025 |
| Main results expected | August 15, 2025 |
| Study ends | October 15, 2025 |
| Registry record updated | April 20, 2025 |
| Trial ID | NCT06936397 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 18 to 55 diagnosed with schizophrenia who are clinically stable and able to provide informed consent.
✕Probably not a fit
Patients with current or past substance use disorders, significant neurological illnesses, or those with severe cognitive impairments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effects of Cognitive Remediation Therapy (CRT) on cognitive and emotional functioning in individuals with schizophrenia. It involves a randomized controlled design with 60 participants, including 30 diagnosed with schizophrenia and 30 healthy controls. Participants with schizophrenia will receive CRT over 12 weeks, focusing on enhancing attention, memory, and emotional regulation through structured exercises. The study will utilize EEG and GSR measurements to assess changes in brain activity and emotional responses before and after the intervention.
Why it matters
Potential benefit: If successful, this therapy could significantly enhance cognitive and emotional functioning in patients with schizophrenia, leading to improved quality of life.
How similar studies have gone: Previous studies have shown promising results for cognitive remediation therapies in schizophrenia, suggesting potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria (Schizophrenia Group): * Diagnosed with schizophrenia according to DSM-5 criteria * Age between 18 and 55 years * Clinically stable (no hospitalization or medication change within 1 month) * Minimum primary school education * Able to provide informed consent * Right-handed (for EEG protocol consistency) Inclusion Criteria (Healthy Control Group): * No history of psychiatric or neurological disorders * Age- and gender-matched to schizophrenia group * No current medication affecting CNS * Able to provide informed consent * Right-handed Exclusion Criteria (Both Groups): * Current or past substance use disorder (within the past year) * Comorbid neurological illness (e.g., epilepsy, traumatic brain injury) * Current use of benzodiazepines or medications that significantly affect cognitive function * Intellectual disability or MoCA score \< 20 * Visual or hearing impairments that could interfere with task performance * Participation in a psychological intervention in the last 3 months
Where it's running
-
Beykoz University
Istanbul, Turkey (Türkiye) Recruiting
Study contacts
- Principal investigator: Metin Çınaroğlu, Phd — Istanbul Nisantasi University
- Study coordinator: Eda Yılmazer, Phd
- Email: edayilmazer@beykoz.edu.tr
- Phone: 00905322575880
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
New flutemetamol F18 formulation to see if it works as well as current for brain amyloid imaging
Researchers are testing a new flutemetamol F18 formulation (GE-287) to see if it identifies brain amyloid as accurately as the current formulation in people 50 and older who are undergoing amyloid PET scans for cognitive decline.
-
Longevity Metrics AI/ML Development Study
Researchers are testing AI models that score health screening tests and predict outcomes like life expectancy for adults, using ongoing follow-up data.
-
Immersive nature-based wellbeing program for older adults with cognitive impairment
A nature-inspired immersive virtual reality program is being tested to see if it can improve well-being and daily function for older adults with mild to moderate cognitive impairment.
-
Hesperidin for better thinking in overweight older adults
In adults aged 55–75 who are overweight, taking hesperidin or a placebo for 10 weeks will show whether the citrus flavonoid can improve thinking skills like memory, attention, and problem-solving.
-
Structured Receptive Music to Help with Care During Bathing for People with Dementia
A structured daily music program used during hygiene care is being tested to see if it reduces refusals of care by residents with dementia in French nursing homes.
-
Risk of delirium and cognitive problems after TUR-P in older adults
This study tests whether certain perioperative factors can predict delirium and postoperative cognitive dysfunction in people aged 65 and older undergoing transurethral resection.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.